Antibody Validation Market size is expected to reach USD 1000 Billion by the end of 2035, growing at a 14% CAGR during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of antibody validation was USD 300 Billion. This growth of the market is anticipated to be influenced on account of growing cases of COVID-19. A large number of people were found to have symptoms of COVID-19 but were not been tested. Hence, due to this, the COVID-19 antibody validation demand was boosted. For instance, to treat COVID-19, an estimated 70 monoclonal antibodies are currently being developed or are through clinical studies.
Moreover, similar to COVID-19 there are numerous other diseases that are set to spread among people. These diseases include Ebola, Marburg virus disease, Lassa fever, MERS-CoV, SARS, and more. However, most of these diseases have no vaccine and research is yet to be conducted. These diseases are referred to as "Disease X," a pandemic-causing sickness that would never have been encountered by mankind before. COVID-19 has been identified as Disease X, prompting scientists to rush to discover therapies and vaccinations to combat it. Hence, in order to avoid the covid19 situation in the coming years, the demand for antibody validation is growing.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~ 14% |
|
Base Year Market Size (2022) |
~ USD 300 Billion |
|
Forecast Year Market Size (2035) |
~ USD 1000 Billion |
|
Regional Scope |
|
Growth Drivers
Over 80 distinct autoimmune illnesses afflict over 3% of the world's population, the most prevalent of which are type 1 diabetes, rheumatoid arthritis, multiple sclerosis, lupus, psoriasis, Crohn's disease, and scleroderma. A person with an autoimmune disease is expected to have a weak immune system that has difficulty distinguishing between harmful antigens and healthy tissue. Due to this, the body starts a reaction that kills healthy tissues. Here, antibodies play a crucial role in building a strong immune system. Therefore, there has been growing research on antibodies, further boosting market growth.
In addition to cardiovascular disorders, cancer is one of the main causes of death in the world. Over the past few decades, significant advancements have been made in the areas of early detection, efficient treatment, and follow-up, providing oncologists with strong tools in the fight against cancer. To lower mortality, improve patient quality of life, and extend patients' lives without developing an illness, additional research is necessary. Moreover, some autoantibodies have been demonstrated to be useful for early identification and cancer staging, as well as monitoring tumor regression throughout treatment and follow-up. However, in order to find more benefits, antibody validation is growing.
Western blot, ELISA, flow cytometry, and IHC are examples of common antibody validation techniques. These tried-and-true techniques are convenient for most researchers. The manufacturer or the researcher must validate the antibody for each application, which could make the validation procedure time-consuming. Hence, some researchers are working on new strategies along with old techniques. Genetic techniques, separate antibody tactics, and tagged protein expression are instances of these strategies.
Challenges
Limited Life Span of Host Animal
Product Type (Monoclonal Antibodies, Polyclonal Antibodies, Anti-Body Drug Complexes)
Antibody validation market from the monoclonal antibodies segment is poised to garner the highest revenue by the end of 2035. Monoclonal antibodies, commonly referred to as mABS, are generated in a lab and have the ability to bind to particular targets in the body, such as antigens on the surface of cancer cells. Monoclonal antibodies (mABs) come in many varieties, and each mAB is made to attach to a specific antigen. Direct medication, toxin, or radioactive substance delivery to cancer cells is possible by using them alone or in combination with other agents. Monoclonal antibodies' rapid application in the detection and treatment of cancer, organ transplant rejection, inflammatory and autoimmune diseases, nervous system disorders, and migraines is one of the main drivers boosting their sales. Additionally, there are now more clinical studies and FDA-approved monoclonal antibody treatments than ever before, which is propelling this segment’s revenue growth.
End User (Pharmaceutical & Biotechnological Firms, Contact Research Organizations, Research Institutes)
The pharmaceutical & biotechnology firms segment is expected to have noteworthy growth over the projected period. Research antibodies are frequently used in drug development for the discovery and measurement of biomarkers as well as other analytical procedures, which is what is driving this segment. Rapid investments in pharmacy, technical improvements in biotechnology, and research in pharmaceutical labs are driving up demand for the antibody validation market.
Our in-depth analysis of the global market includes the following segments:
|
Product Type |
|
|
Disease Indication |
|
|
End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
North American Market Forecast
The antibody validation market in North America is projected to garner the highest revenue in the near future, backed by the growing prevalence of HIV, along with rising investment in research and development. According to projections, 1.2 million Americans had HIV by the end of 2021. Hence, there have been various clinical trials conducted in this region in order to stop the spread of HIV. Moreover, the prevention of malaria has also gained focus in this region, which is further boosting market growth.
European Market Statistics
Europe antibody validation market is set to have significant growth between 2023 and 2035. Market revenue growth in this region is being driven by the biotechnology and pharmaceutical industries' growing use of technology. Additionally, growing partnerships, collaborations, and mergers & acquisitions are anticipated to fuel market expansion in the upcoming years.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: The major factors driving the growth of the market are the growing prevalence of autoimmune disease, the rise in the need for early detection of cancer, and the advancement of strategies.
Ans: The market size of antibody validation is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 – 2035.
Ans: The major players in the market are General Electric, Merck KGaA, Thermo Fisher Scientific Inc., F. Hoffmann La-Roche Ltd, and more.
Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
Ans: The market is segmented by product type, disease indication, end user and by region.
Ans: The monoclonal antibodies segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Ans: Require high investment, variation included in antibody techniques, and limited life span of host animal are estimated to be the growth hindering factors for the market expansion.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?